Business
Matthew Moore Joins Arcutis as Chief Business Officer
WESTLAKE VILLAGE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"text","content":"WESTLAKE VILLAGE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Matthew Moore has joined the company as Chief Business Officer. Mr. Moore brings to Arcutis over 20 years of strategy, transaction and operations experience in the biopharmaceutical industry. Most recently, he served as Vice President, Corporate Business Development and Alliance Management at Allergan, where he led worldwide strategy and business development for the company’s $4B+ Medical Aesthetics business unit. “We are thrilled to add Matt to our executive team. Like the rest of our senior team, Matt brings a deep understanding of dermatology markets, and he adds important expertise in corporate strategy, business development, and alliance management. His extensive experience creating shareholder value through successful business development will be a key enabler as we continue to build Arcutis into one of the industry’s leading dermatology companies,” said Frank Watanabe, Arcutis’ President and Chief Executive Officer. “We at Arcutis are focused on elevating the standard of care for dermatological diseases, and his strategic insights and deal execution will play an important role in helping us to realize that goal.” “I am delighted to join Arcutis at such an exciting time for the company,” said Mr. Moore. “Arcutis has established itself as a leader in medical dermatology and is uniquely positioned to fill the innovation gap in this therapeutic area. I have been impressed by the pace of progress achieved to date, and look forward to working with the team to help make Arcutis the preeminent, innovation-driven medical dermatology company.” During his tenure at Allergan and its predecessor companies, Actavis and Forest Labs, Mr. Moore was responsible for creating and executing business development growth strategies across multiple therapeutic areas including medical aesthetics, neuroscience, anti-infectives and hospital products. In addition, Mr. Moore served as a key deal team member in Actavis’ transformational acquisition of Allergan and Allergan’s ultimate sale to AbbVie. Prior to Allergan, Mr. Moore held executiv...